This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fox, J. L.
Right arrow Articles by Busch, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, J. L.
Right arrow Articles by Busch, M. P.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, January 2006, p. 33-36, Vol. 13, No. 1
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.1.33-36.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Immunoglobulin G Avidity in Differentiation between Early and Late Antibody Responses to West Nile Virus

Janet L. Fox,1 Stuart L. Hazell,1* Leslie H. Tobler,2 and Michael P. Busch2

Panbio Ltd., Brisbane, Australia,1 Blood Systems Research Institute, San Francisco, California2

Received 15 April 2005/ Accepted 24 October 2005

In 1999 West Nile virus (WNV) surfaced in the United States in the city of New York and spread over successive summers to most of the continental United States, Canada, and Mexico. Because WNV immunoglobulin M (IgM) antibodies have been shown to persist for up to 1 year, residents in areas of endemicity can have persistent WNV IgM antibodies that are unrelated to a current illness with which they present. We present data on the use of IgG avidity testing for the resolution of conflicting data arising from the testing of serum or plasma for antibodies to WNV. Thirteen seroconversion panels, each consisting of a minimum of four samples, were used. All samples were tested for the presence of WNV IgM and IgG antibodies, and the avidity index for the WNV IgG-positive samples was calculated. Panels that exhibited a rise in the WNV IgM level followed by a sequential rise in the WNV IgG level were designated "primary." Panels that exhibited a marked rise in the WNV IgG level followed by a sequential weak WNV IgM response and that had serological evidence of a prior flavivirus infection were designated "secondary." All samples from the "primary" panels exhibited low avidity indices (less than 40%) for the first 20 to 30 days after the recovery of the index sample (the sample found to be virus positive). All of the "secondary" samples had elevated WNV IgG levels with avidity indices of ≥55%, regardless of the number of days since the recovery of the index sample. These data demonstrate that it is possible to differentiate between recent and past exposure to WNV or another flavivirus through the measurement of WNV IgG avidity indices.

* Corresponding author. Mailing address: Panbio Limited, 532 Seventeen Mile Rocks Road, Sinnamon Park, Queensland 4073, Australia. Phone: 617 3363 7100. Fax: 617 3363 7199. E-mail: stuart_hazell{at}panbio.com.

Clinical and Vaccine Immunology, January 2006, p. 33-36, Vol. 13, No. 1
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.1.33-36.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»